Interaction of Na2B12H11SH with liposomes:: Influence on zeta potential and particle size

被引：18

作者：

Awad, D ^{[1
]}

Tabod, I

Lutz, S

Wessolowski, H

Gabel, D

机构：

[1] Univ Bremen, Dept Chem, D-28334 Bremen, Germany

[2] Univ Bremen, Inst Environm Proc Engn, D-28334 Bremen, Germany

来源：

JOURNAL OF ORGANOMETALLIC CHEMISTRY | 2005年 / 690卷 / 11期

关键词：

BSH; liposomes; liposome size; zeta potential;

D O I：

10.1016/j.jorganchem.2005.01.013

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

The interaction of Na2B12H11SH (BSH) with liposomes has been studied. BSH is a compound used clinically in boron neutron capture therapy of glioblastoma, and is known to enter tumor cells. Liposomes were used as a model for studying the interaction of BSH with cell membranes. BSH led to changes in the zeta potential of liposomes consisting of DODAB (dioctadecyldimethylammonium bromide) alone or with DOPC (dioleylphosphatidylcholine) or DOPE (dioleylphosphatidylethanolamine). It also led to changes of the size of DODAB liposomes, with a maximum size at small zeta potentials. A firm binding of BSH with the head groups of the lipid must be assumed. (c) 2005 Elsevier B.V. All rights reserved.

引用

收藏

页码：2732 / 2735

页数：4

相关论文

共 15 条

[1] Cationic liposome-mediated gene delivery: Biophysical study and mechanism of internalization [J].

Almofti, MR ;

Harashima, H ;

Shinohara, Y ;

Almofti, A ;

Baba, Y ;

Kiwada, H .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 410 (02) :246-253

[2]

[Anonymous], 1987, CHEM EXPRESS

[3] Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture [J].

Gabel, D ;

Preusse, D ;

Haritz, D ;

Grochulla, F ;

Haselsberger, K ;

Fankhauser, H ;

Ceberg, C ;

Peters, HD ;

Klotz, U .

ACTA NEUROCHIRURGICA, 1997, 139 (07) :606-612

[4] SYNTHESIS OF S-ALKYL AND S-ACYL DERIVATIVES OF MERCAPTOUNDECAHYDRODODECABORATE, A POSSIBLE BORON CARRIER FOR NEUTRON-CAPTURE THERAPY [J].

GABEL, D ;

MOLLER, D ;

HARFST, S ;

ROSLER, J ;

KETZ, H .

INORGANIC CHEMISTRY, 1993, 32 (11) :2276-2278

[5] CLINICAL PHASE-I STUDY OF NA2B12H11SH (BSH) IN PATIENTS WITH MALIGNANT GLIOMA AS PRECONDITION FOR BORON NEUTRON-CAPTURE THERAPY (BNCT) [J].

HARITZ, D ;

GABEL, D ;

HUISKAMP, R .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (05) :1175-1181

[6] Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial [J].

Hideghéty, K ;

Sauerwein, W ;

Wittig, A ;

Götz, C ;

Paquis, P ;

Grochulla, F ;

Haselsberger, K ;

Wolbers, J ;

Moss, R ;

Huiskamp, R ;

Fankhauser, H ;

de Vries, M ;

Gabel, D .

JOURNAL OF NEURO-ONCOLOGY, 2003, 62 (01) :145-156

[7] Interaction of mercaptoundecahydrododecaborate (BSH) with phosphatidylcholine: relevance to boron neutron capture therapy [J].

Kageji, T ;

Otersen, B ;

Gabel, D ;

Huiskamp, R ;

Nakagawa, Y ;

Matsumoto, K .

BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1998, 1391 (03) :377-383

[8] Optimal timing of neutron irradiation for boron neutron capture therapy after intravenous infusion of sodium borocaptate in patients with glioblastoma [J].

Kageji, T ;

Nagahiro, S ;

Kitamura, K ;

Nakagawa, Y ;

Hatanaka, H ;

Haritz, D ;

Grochulla, F ;

Haselsberger, K ;

Gabel, D .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (01) :120-130

[9] Noncoordinating anions - Fact or fiction? A survey of likely candidates [J].

Krossing, I ;

Raabe, I .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2004, 43 (16) :2066-2090

[10] Boron neutron capture therapy - Clinical brain tumor studies [J].

Nakagawa, Y ;

Hatanaka, H .

JOURNAL OF NEURO-ONCOLOGY, 1997, 33 (1-2) :105-115